Every material Form 8-K Labcorp has filed with the SEC since April 29, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Labcorp said on November 4, 2026 that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10, 2026. A live audio webcast will be available on the company's investor relations website and archived for 180 days, so shareholders can access the remarks. The filing is an administrative disclosure and includes no financial results.
Fireside chat with CFO Julia Wang on November 10, 2026 at 8:45 a.m. ET
Live audio webcast at ir.labcorp.com, archived for replay for 180 days
Press release dated November 4, 2026 furnished as Exhibit 99.1
Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9% from a year earlier, and adjusted EPS of $4.78, up 14.5%. Diluted EPS rose 3.3% to $3.22, and the company raised its full-year 2026 revenue growth and adjusted EPS guidance. For shareholders, the headline measures improved and the higher outlook is the most significant change in the release.
Q3 2026 revenue was $3.81 billion versus $3.56 billion, up 6.9%; organic growth was 5.5%.
Diluted EPS was $3.22 versus $3.12, up 3.3%; adjusted EPS was $4.78 versus $4.18, up 14.5%.
Full-year 2026 adjusted EPS guidance was raised to $18.30 to $18.70 from $18.10 to $18.55; enterprise revenue growth guidance was raised to 5.9% to 6.7%.
Three acquisition agreements were signed after the quarter ended, including Millennium Health and the Myriad Genetics Prenatal Health business, subject to regulatory approvals.
Labcorp's Board of Directors declared a cash dividend of $0.72 per share of common stock, announced October 21, 2026. The dividend is payable December 11, 2026, to holders of record at the close of business on November 24, 2026. The filing contains no earnings, guidance, or other financial results.
Cash dividend of $0.72 per share of common stock declared October 21, 2026
Payable December 11, 2026
Record date is the close of business on November 24, 2026
Labcorp said executive Megan D. Bailey will resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., currently President of Early Development Research Laboratories and Chief Medical and Scientific Officer, will take a broader role effective September 1, 2026, overseeing Biopharma Laboratory Services along with the Early Development Research Laboratories and Central Laboratories businesses.
Megan D. Bailey notified the company of her resignation on August 11, 2026, effective September 4, 2026
Brian J. Caveney, M.D., takes on expanded role effective September 1, 2026
Caveney's new title: EVP and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer
The filing does not state a replacement for Bailey's former role or any financial terms
Labcorp reported second-quarter 2026 revenue of $3.73 billion, up 5.8% from a year earlier, and diluted EPS of $3.64, up from $2.84. The company raised its full-year 2026 adjusted EPS guidance to $18.10 to $18.55 and increased its share repurchase authorization by $1.0 billion, leaving $1.4 billion remaining, which points to stronger results and more capital returned to shareholders.
Q2 2026 revenue was $3.73 billion versus $3.53 billion, up 5.8%
Adjusted EPS was $4.99 versus $4.35, up 14.9%; diluted EPS was $3.64 versus $2.84
2026 adjusted EPS guidance raised to $18.10 to $18.55, up 30 cents at the midpoint
Share repurchase authorization increased by $1.0 billion, bringing remaining authorization to $1.4 billion
Labcorp reported first-quarter 2026 revenue of $3.54 billion, up 5.8% from $3.35 billion a year earlier, and diluted EPS of $3.35 versus $2.52. The company raised its full-year 2026 revenue and adjusted EPS guidance, with the adjusted EPS range now $17.70 to $18.35 from $17.55 to $18.25. Headline profit and revenue measures improved, while total debt rose to $6.33 billion at quarter end due to pre-funding of maturing debt.
Q1 2026 revenue $3.54 billion vs. $3.35 billion, up 5.8%; diluted EPS $3.35 vs. $2.52
Q1 2026 adjusted EPS $4.25 vs. $3.84, up 10.6%
Full-year 2026 adjusted EPS guidance raised to $17.70–$18.35 from $17.55–$18.25; revenue guidance raised to 5.0%–6.1% growth
Quarterly dividend of $0.72 per share declared April 9, 2026, payable June 11, 2026 to holders of record May 29, 2026
Labcorp and its subsidiary Laboratory Corporation of America Holdings signed a $750 million senior unsecured term loan with Wells Fargo as administrative agent, fully funded on March 20, 2026. The loan matures March 20, 2028 and carries a floating rate of SOFR plus 0.700% or a base rate with a 0% margin. It adds to the company's debt obligations and includes a leverage ratio covenant of 4.0 to 1.0.
$750 million senior unsecured term loan, fully funded on March 20, 2026
Matures March 20, 2028; floating rate of SOFR plus 0.700% or base rate plus 0%
Leverage ratio covenant of not more than 4.0 to 1.0, with a temporary increase to 4.5 to 1.0 allowed after a material acquisition
Wells Fargo Bank, National Association is administrative agent; PNC Bank, National Association is syndication agent
Labcorp reported fourth-quarter 2025 revenue of $3.52 billion, up from $3.33 billion, and full-year revenue of $13.95 billion, up from $13.01 billion. Full-year diluted EPS rose to $10.46 from $8.84, and the company provided 2026 guidance calling for adjusted EPS of $17.55 to $18.25, compared with $16.44 in 2025. Fourth-quarter restructuring and other charges of $110.8 million, up from $11.4 million a year earlier, were a notable offsetting item.
Q4 2025 diluted EPS was $1.98 vs $1.70 a year earlier; Q4 adjusted EPS was $4.07 vs $3.45
2026 guidance: revenue of $14.61 billion to $14.79 billion and free cash flow of $1.24 billion to $1.36 billion
Q4 2025 free cash flow was $490.3 million vs $665.1 million, which the company attributed to working capital timing
Quarterly dividend of $0.72 per share is payable March 12, 2026, to holders of record on February 27, 2026
Labcorp Holdings appointed John H. Sampson, M.D., Ph.D., as a board member effective February 9, 2026, and named him to the Quality and Compliance Committee. Sampson is vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine and previously held senior leadership roles at Duke University Health System. The filing describes a board addition with no financial results, guidance or deal terms attached.
Board appointment effective February 9, 2026; Board approved the appointment on February 6, 2026
Sampson joins the Quality and Compliance Committee
Sampson will receive director compensation under the company's program described in its April 4, 2025 proxy statement
Sampson is vice chancellor for health affairs and dean at the University of Colorado Anschutz School of Medicine
Labcorp amended its receivables purchase agreement on January 28, 2026, extending the scheduled termination date to January 26, 2029. The amendment adds a committed $125 million accordion that lets the subsidiary raise the facility limit from $700 million to up to $825 million on or before May 29, 2026. The filing describes this as a financing update rather than a change in operating results.
Scheduled termination date extended to January 26, 2029
Committed $125 million accordion lets facility limit rise from $700 million to up to $825 million by May 29, 2026
Removed the 0.10% SOFR adjustment previously added to capital accruing yield
Labcorp Receivables assets are not available to pay Labcorp's other creditors
Labcorp said Mark Schroeder, Executive Vice President and President of Diagnostics Laboratories and Chief Operations Officer, notified the company on December 9, 2025, of his intention to retire. His retirement takes effect April 1, 2026, giving the company about three months to plan for the departure of a senior operating executive.
Mark Schroeder notified Labcorp of his retirement on December 9, 2025.
Retirement is effective April 1, 2026.
Schroeder held the roles of EVP and President, Diagnostics Laboratories, and Chief Operations Officer.
The filing does not name a successor or describe any compensation arrangements.
Labcorp announced that director Dr. D. Gary Gilliland will retire from its board effective December 31, 2025, having notified the board on December 5, 2025. The filing reports no financial results, no successor named, and no change in company guidance, so the direct effect on shareholders appears limited to board composition.
Dr. D. Gary Gilliland notified the board of his retirement decision on December 5, 2025; the retirement takes effect December 31, 2025.
Gilliland joined the board in 2014 and served on the Audit Committee and Quality and Compliance Committee.
Chairman and CEO Adam Schechter credited Gilliland with more than 10 years of service; lead independent director Dr. Garheng Kong cited his leadership and strategic insight.
Labcorp's Board of Directors appointed Victor Bulto, President of Novartis U.S. and a member of the Novartis Executive Committee, as a director effective December 1, 2025. The filing describes the appointment as a board addition and includes no financial results, guidance, or changes to executive roles.
Board appointment made on November 20, 2025, effective December 1, 2025
Bulto has served as President of Novartis U.S. and on the Novartis Executive Committee since April 2022
Bulto will receive director compensation under Labcorp's director compensation program described in the April 4, 2025 proxy statement
Labcorp reported third-quarter 2025 revenue of $3.56 billion, up from $3.28 billion, and diluted EPS of $3.12, up from $2.00. It raised its full-year adjusted EPS guidance midpoint by $0.05 and its free cash flow guidance midpoint by $25 million, but lowered its revenue growth guidance midpoint by 40 basis points, citing currency and acquisition timing.
Q3 revenue was $3.56 billion versus $3.28 billion a year earlier; adjusted EPS was $4.18 versus $3.50.
Full-year adjusted EPS guidance is now $16.15 to $16.50, with the midpoint raised by $0.05.
Full-year revenue growth guidance is 7.4% to 8.0%, with the midpoint lowered 40 basis points due to currency and acquisition timing.
Free cash flow guidance is $1.17 billion to $1.29 billion, with the midpoint raised by $25 million.
Labcorp reported second-quarter 2025 revenue of $3.53 billion, up from $3.22 billion a year earlier, and diluted EPS of $2.84 versus $2.43. The company raised its full-year 2025 guidance for enterprise revenue, adjusted EPS and free cash flow, which is a positive signal for shareholders on both sales and earnings.
Q2 revenue $3.53 billion vs $3.22 billion; diluted EPS $2.84 vs $2.43; adjusted EPS $4.35 vs $3.94
Adjusted EPS guidance range narrowed to $16.05 to $16.50 from $15.70 to $16.40; midpoint raised by $0.23
Free cash flow guidance of $1.13 billion to $1.28 billion, midpoint raised by $25 million
Quarterly dividend of $0.72 per share declared July 10, 2025, payable September 11, 2025; $200 million of stock repurchased in the quarter
On June 27, 2025, Labcorp Holdings and its subsidiary Laboratory Corporation of America Holdings entered a Fourth Amended and Restated Credit Agreement with Bank of America as administrative agent. The $1 billion senior unsecured revolving facility replaces the existing facility and extends its maturity from April 30, 2026 to June 27, 2030. The company had no outstanding borrowings under the facility as of the closing date.
Facility size of $1,000,000,000, including a $100,000,000 swingline subfacility and a $150,000,000 letter of credit sublimit
Maturity extended from April 30, 2026 to June 27, 2030
No outstanding borrowings as of June 27, 2025; the facility can be increased by up to $500,000,000, subject to conditions
Financial covenant requires a leverage ratio of not more than 4.0 to 1.0, with a temporary increase to 4.5 to 1.0 after a material acquisition
At its 2025 Annual Meeting on May 15, 2025, Labcorp shareholders elected all 10 director nominees to terms expiring at the 2026 meeting and approved the 2025 Omnibus Incentive Plan and 2025 Employee Stock Purchase Plan. Shareholders also ratified Deloitte & Touche LLP as the independent auditor for 2025 and approved executive pay in an advisory vote.
Holders of 76,049,607 of 83,668,573 shares on the March 20, 2025 record date were represented, meeting the quorum.
The 2025 Omnibus Incentive Plan received 65,957,167 votes for and 3,916,664 against.
The 2025 Employee Stock Purchase Plan received 69,852,552 votes for and 111,189 against.
Deloitte & Touche LLP was ratified for the year ending December 31, 2025, with 75,696,303 votes for and 297,066 against.
Labcorp reported first-quarter 2025 revenue of $3.35 billion, up from $3.18 billion a year earlier, and adjusted EPS of $3.84, up from $3.68. GAAP diluted EPS fell to $2.52 from $2.69. The company raised the midpoint of its full-year adjusted EPS guidance by $0.05 and reaffirmed its revenue and free cash flow guidance, which matters to shareholders because it signals higher expected adjusted profit for 2025.
Q1 2025 revenue was $3.35 billion versus $3.18 billion in Q1 2024.
Diluted EPS was $2.52 versus $2.69; adjusted EPS was $3.84 versus $3.68.
2025 adjusted EPS guidance is $15.70 to $16.40, with the midpoint raised $0.05.
Revenue guidance of 6.7% to 8.0% and free cash flow guidance of $1.10 billion to $1.25 billion were reaffirmed.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Labcorp filing is on SEC EDGAR ↗. 8-K briefs of other companies →